Clinical Trials Browser

INDUSTRY × Has results × Bortezomib × Clear all

NCT01009840 2026-05-13

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Phase 2 Completed

30 enrolled 14 charts

Multiple Myeloma

NCT04181827 2026-05-11

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT04246047 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma

NCT06868654 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

72 enrolled 10 charts

Multiple Myeloma

NCT06868667 2026-04-23

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Phase 3 Active not recruiting

395 enrolled 11 charts 1 FDA

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1/2 Active not recruiting

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Phase 3 Completed

416 enrolled 28 charts 2 FDA

Amyloidosis

NCT05564052 2025-10-07

VEGA

Phase 2 Completed

36 enrolled 18 charts

Lymphoma, Mantle-Cell

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 2 FDA

Multiple Myeloma

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT04304144 2025-03-05

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Phase 2 Completed

25 enrolled 14 charts

Immunoglobulin Light-chain Amyloidosis

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT02874742 2025-02-04

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

224 enrolled 19 charts

Multiple Myeloma

NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Phase 1/2 Completed

20 enrolled 9 charts

GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

NCT02654990 2024-07-12

PANORAMA_3

Phase 2 Completed

248 enrolled 28 charts

Multiple Myeloma, Recurrence

NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Phase 1/2 Completed

95 enrolled 13 charts

LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Multiple Myeloma

NCT01734928 2023-06-06

OPTIMISMM

Phase 3 Completed

559 enrolled 16 charts

Multiple Myeloma

NCT03481556 2022-12-19

ANCHOR

Phase 1/2 Terminated

56 enrolled 22 charts

Multiple Myeloma

NCT01568866 2022-11-14

ENDEAVOR

Phase 3 Completed

929 enrolled 21 charts

Multiple Myeloma

NCT02951819 2021-10-08

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Phase 2 Completed

101 enrolled 17 charts

Multiple Myeloma

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00858234 2021-04-09

MK-0683-098

Phase 1 Completed

9 enrolled 9 charts

Multiple Myeloma

NCT00773838 2021-04-01

MK-0683-095

Phase 2 Completed

143 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Completed

241 enrolled 31 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03117361 2020-12-02

Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

Phase 2 Terminated

10 enrolled 37 charts

Multiple Myeloma

NCT02100657 2020-10-12

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Phase 1 Completed

39 enrolled 30 charts

Multiple Myeloma

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02902965 2020-03-16

Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

74 enrolled 20 charts

Multiple Myeloma

NCT02928029 2020-02-26

Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

Phase 1/2 Terminated

7 enrolled 9 charts

Multiple Myeloma

NCT00765102 2019-11-25

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Phase 2 Terminated

32 enrolled 14 charts

Multiple Myeloma

NCT00401843 2019-11-19

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

307 enrolled 13 charts

Multiple Myeloma

NCT02290431 2019-11-18

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

31 enrolled 19 charts

Multiple Myeloma, Recurrence

NCT01602224 2019-10-08

A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Phase 2 Completed

220 enrolled 20 charts

Multiple Myeloma

NCT01818752 2019-08-26

CLARION

Phase 3 Completed

955 enrolled 20 charts

Multiple Myeloma

NCT00920556 2019-02-27

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Phase 2 Terminated

24 enrolled 24 charts

Multiple Myeloma

NCT02720510 2018-07-24

PANORAMA4

Phase 2 Terminated

6 enrolled 7 charts

Multiple Myeloma

NCT00722137 2018-07-12

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 3 Completed

487 enrolled 20 charts

Lymphoma, Mantle-Cell

NCT01478048 2018-05-21

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

185 enrolled 19 charts

Multiple Myeloma

NCT01083602 2017-12-21

MACS1271

Phase 2 Completed

55 enrolled 11 charts

Multiple Myeloma, Recurrence